- Education
- Source: Campus Sanofi
- 23 Jul 2025
The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS

Prescribing information is available by clicking the links at the bottom of the page
The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS
Length: 6:59
Dr Rani Khatib discusses the reasons why post-MI secondary prevention clinics should be established, explains the Leeds cardiometabolic medicines optimisation pathway and their multidisciplinary innovative medicines clinic for PCSK9i & statin intolerance, the benefits to patients and healthcare system, and the challenges to overcome.
Videos From the Same Series
%20(18).png)
Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)
%20(19).png)
What's the Future of Secondary Care Lipid Services | Praluent® (alirocumab)
%20(20).png)
Strengthening the Interface between Primary and Secondary Care | Praluent® (alirocumab)
%20(18).png)
Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent® (alirocumab)
%20(19).png)
What's the Future of Secondary Care Lipid Services | Praluent® (alirocumab)
%20(20).png)
Strengthening the Interface between Primary and Secondary Care | Praluent® (alirocumab)
.png)
MAT-XU-2503044 (v1.0) Date of Preparation: July 2025